Inhibition by brefeldin A of the specific B cell antigen presentation to MHC class II-restricted T cells.
We have shown previously that specific Ag presentation is prevented by the inhibition of protein synthesis but nonspecific presentation is not. In the present paper, Ag presentation by Ag-specific B cells was examined for sensitivity to brefeldin A (BFA), which blocks protein export from the endoplasmic reticulum. A20-HL B lymphoma expressing surface receptors specific for TNP was used as a B cell, and TNP-OVA was used as a specific Ag. The presence of BFA during pulsing of A20-HL cells with TNP-OVA inhibited the ability of the pulsed cells to stimulate 42-6A T cell clone, specific for OVA323-339 and Iad. The inhibition was not due to nonspecific toxicity of BFA, because the presence of BFA during pulsing of A20-HL cells with OVA323-339 did not affect their APC function. Ag binding to the receptor on A20-HL cells and internalization by the cells were observed in the presence of BFA. Thus, BFA might inhibit intracellular processing of specific Ag or intracellular complex formation of antigenic peptide from specific Ag with MHC class II molecules. Nonspecific Ag presentation by A20-HL cells, however, was resistant to BFA. A20-HL cells pulsed with OVA in the presence of BFA, even after fixation, could stimulate 42-6A cells to produce IL-2, although the IL-2 production was lower than that induced by A20-HL cells pulsed in the absence of BFA. These results suggest that the processing pathways for specific Ag and nonspecific Ag are different from each other, at least partly, in A20-HL cells.
Department of Allergology, University of Tokyo, Japan.
T
T
Kakiuchi
A
A
Takatsuki
M
M
Watanabe
H
H
Nariuchi
D000818:Animals; D000938:Antigen-Presenting Cells / Q000187:drug effects*; D001402:B-Lymphocytes / Q000276:immunology*; D001692:Biological Transport / Q000187:drug effects; D020126:Brefeldin A; D003517:Cyclopentanes / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D004306:Dose-Response Relationship, Immunologic; D004721:Endoplasmic Reticulum / Q000187:drug effects; D000949:Histocompatibility Antigens Class II / Q000276:immunology; D066298:In Vitro Techniques; D007376:Interleukin-2 / Q000096:biosynthesis; D008213:Lymphocyte Activation; D051379:Mice; D010047:Ovalbumin / Q000276:immunology; D014301:Trinitrobenzenes / Q000276:immunology
D003517:Cyclopentanes; D000949:Histocompatibility Antigens Class II; D007376:Interleukin-2; D014301:Trinitrobenzenes; D020126:Brefeldin A; D010047:Ovalbumin